Sequelae in male rabbits following developmental exposure to p,p'-DDT or a mixture of p,p'-DDT and vinclozolin: cryptorchidism, germ cell atypia, and sexual dysfunction.
Rabbit does (7-9 per group) were treated daily per orum from gestation day 15 through post-natal week 4 to provide per kg body wt 25 micaromol (low) or 250 micromol (high) p,p'-DDT or a mixture of DDT and vinclozolin (12.5 and 125 micromol each). Developmental as well as post-pubertal reproductive sequelae of male progeny were studied. Testicular descent in some pups was impaired by DDT. Serum LH or testosterone was not affected. FSH was lower in mixture- but not in DDT-exposed rabbits. Lack of sexual interest, penile erection and ejaculation were observed in some mixture rabbits. Sperm counts were unaffected, but morphologically normal spermatozoa were fewer; nuclear and acrosomal morphogenesis was disrupted. Atypical germ cells resembling carcinoma in situ were found. Also considering data for vinclozolin [Veeramachaneni DNR, Palmer JS, Amann RP, Kane CM, Higuchi TT, Pau K-YF. Disruption of sexual function, FSH secretion, and spermiogenesis in rabbits following developmental exposure to vinclozolin, a fungicide. Reproduction 2006;131:805-16], we concluded that DDT causes cryptorchidism and germ cell atypia, vinclozolin permanently disrupts FSH secretion and sexual function, and the mixture causes the full spectrum of dysgenesis.
Veeramachaneni
D N R
DN
Animal Reproduction and Biotechnology Laboratory, Colorado State University, Fort Collins, CO 80523-1683, United States. D_N_Rao.Veeramachaneni@colostate.edu
Palmer
J S
JS
Amann
R P
RP
Pau
K-Y F
KY
D000726:Androgen Antagonists / Q000008:administration & dosage / Q000633:toxicity; D000818:Animals; D003456:Cryptorchidism / Q000139:chemically induced* / Q000196:embryology; D003634:DDT / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D047108:Embryonic Development / Q000187:drug effects; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000503:physiopathology; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D008854:Microscopy, Electron; D008954:Models, Biological; D009845:Oligospermia / Q000139:chemically induced; D010080:Oxazoles / Q000008:administration & dosage / Q000633:toxicity*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011817:Rabbits; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced*; D013091:Spermatogenesis / Q000187:drug effects; D013094:Spermatozoa / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D013737:Testis / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D013739:Testosterone / Q000378:metabolism
D000726:Androgen Antagonists; D010080:Oxazoles; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D003634:DDT; C025643:vinclozolin